Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Vandetanib (Caprelsa™)

Last Updated: 09/15/17

Status: Potential NF2 Clinical Trial

Warning - Dangerous Treatment

Vandetanib (Caprelsa™) has not been in trials specifically for NF2 at this time. Vandetanib was in a trial under the trade name Zactima™ in 2009 for Non-small cell lung cancer. The pharmaceutical company Astrazeneca discontinued Vandetanib under trade name Zactima™ and it is now under the name Caprelsa™ used in the treatment of certain tumors of the thyroid gland.

Zactima™ and Non-small Cell Lung Cancer

Under the name Zactima™, Vandetanib had a high absorption rate and any excess would leave the body unchanged in the form of feces or urine, which is uncommon and something more oral treatments need to do. However while effective as a treatment, in the initial clinical trials a heart condition easily developed, prolonged QT interval. As a result of the side effects only three months after the trial started and several months earlier than trial expected to end, treatment discontinued listed as unfavorable benefit-risk balance.

Caprelsa™ and Thyroid Gland Tumors

More recently Vandetanib has been reintroduced under the name Caprelsa™ in the treatment of certain types of thyroid gland tumors.

Trade Name Caprelsa™ and Zactima™
Other Names Vandetanib, Zactima, ZD6474, 443913-73-3, ZD-6474, 2ivu, ||Zactima, Vandetanib [INN], ZD 6474, S1046_Selleck
Pharmaceutical Company Astrazeneca
Prescription Information DailyMed
Treatment By Pill - Oral
Expectation Size reduction of Meningiomas
Inhibitor tyrosine kinase inhibitor
vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase
Molecular Formula C22H27FN4O2
IUPAC N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
ChemSpider 2338979
PubChem CID 3081361